Chimeric Therapeutics is trading at A$0.01, up 9.09% after rising from the September 1, 2026 close, with no new company-specific announcement or verified catalyst identified for September 2, 2026.
- The latest major disclosure remains the August 19 trial update, which reported halted enrollment following dose-limiting toxicities and planned cost reductions.
- Available sector context is negative and does not clearly explain the gain.